U.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 5 2016 → Feb 6 2016

Media coverage

4

Media coverage

  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletPharmacy Choice
    CountryUnited States
    Date2/6/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletTMC Net
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBusiness Wire
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBusiness Wire
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad